# EDGAR Filing Document

**Accession Number:** 0001827635
**File Stem:** 0001628280-26-028544
**Filing Date:** 2026-4
**Character Count:** 22001
**Document Hash:** 23550e613bcfa6ea801d3272910a0393
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-028544.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001628280-26-028544

**CONFORMED SUBMISSION TYPE**: S-1MEF

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**EFFECTIVENESS DATE**: 20260429

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradermics, Inc
- **CENTRAL INDEX KEY:** 0001827635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843304423
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-1MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295420
- **FILM NUMBER:** 26919545

**BUSINESS ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513
- **BUSINESS PHONE:** 228.372.3376

**MAIL ADDRESS:**
- **STREET 1:** 470 JAMES STREET
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06513

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VeraDermics, Inc
- **DATE OF NAME CHANGE:** 20201008

**As filed with the Securities and Exchange Commission on April 29, 2026**

**Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**VERADERMICS, INCORPORATED**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **84-3304423** |
| **(State or other jurisdiction of incorporation or organization)** | **(Primary Standard Industrial Classification Code Number)** | **(I.R.S. Employer Identification Number)** |

---

**470 James St.**

**New Haven, CT 06513**

**(228) 372-3376**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Reid Waldman, M.D.**

**Chief Executive Officer** 

**Veradermics, Incorporated**

**470 James St.**

**New Haven, CT 06513** 

**(228) 372-3376**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copies to:***

---

| | | |
|:---|:---|:---|
| **Zachary Blume**<br>**Nicholas Roper**<br>**Ropes & Gray LLP**<br>**Prudential Tower**<br>**800 Boylston Street**<br>**Boston, MA 02199-3600**<br>**(617) 951-7000** | **Michael Greco**<br>**General Counsel**<br>**Veradermics, Incorporated**<br>**470 James St.**<br>**New Haven, CT 06513**<br>**(228) 372-3376** | **Divakar S. Gupta**<br>**Ryan Sansom**<br>**Madison A. Jones**<br>**Cooley LLP**<br>**55 Hudson Yards**<br>**New York, NY 10001**<br>**(212) 479-6000** |

---

**Approximate date of commencement of proposed sale to the public:**

**As soon as practicable after this Registration Statement becomes effective.**

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-295356

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.**

------

**Explanatory Note and Incorporation By Reference**

This Registration Statement on Form S-1 (this "Registration Statement") is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"). This Registration Statement relates to the public offering of common stock, par value $0.00001 per share ("Common Stock") and, in lieu of Common Stock to certain investors, pre-funded warrants (the "Pre-Funded Warrants") to purchase shares of Common Stock, of Veradermics, Incorporated (the "Registrant"), contemplated by the Registration Statement on Form S-1 (File No. 333-295356) filed by the Registrant with the Securities and Exchange Commission (the "Commission") on April 27, 2026 (the "Prior Registration Statement") pursuant to the Securities Act, which was declared effective by the Commission on April 29, 2026. The contents of the Prior Registration Statement, including all exhibits thereto, are incorporated by reference into this Registration Statement.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate offering price of shares of Common Stock, or Pre-Funded Warrants, to be offered in the public offering by $56,785,800, which includes additional shares that the underwriters have the option to purchase. The additional shares of Common Stock and Pre-Funded Warrants that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in Exhibit 107 to the Prior Registration Statement.

The required opinion and consents are listed in Part II, Item 16 hereto and filed herewith.

------

**PART II**

**Information Not Required in Prospectus**

**Item 16. Exhibit List**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description of Exhibit** |
| 5.1 | <u>[Opinion of Ropes & Gray LLP](exhibit51-sx1mef.htm)</u> |
| 23.1 | <u>[Consent of Deloitte & Touche LLP independent registered public accounting firm.](exhibit231-sx1mefapril2026.htm)</u> |
| 23.2 | <u>[Consent of Ropes & Gray LLP (included in Exhibit 5.1)](exhibit51-sx1mef.htm)</u> |
| 24.1\* | <u>[Power of Attorney](https://www.sec.gov/Archives/edgar/data/1827635/000162828026027631/follow-on2026pfw.htm#i9c9a8c24881c455b87196ce972cc78e9_298)</u> |
| 107 | <u>[Filing Fee Table](s1mef-exfilingfees.htm)</u> |

---

___________

\*Previously filed on the signature page to the Registrant's Registration Statement on Form S-1 (File No. 333-295356), originally filed with the Securities and Exchange Commission on April 27, 2026 and incorporated by reference herein.

------

**Signatures**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, Connecticut, on the 29th day of April, 2026.

---

| | |
|:---|:---|
| **VERADERMICS, INCORPORATED** | **VERADERMICS, INCORPORATED** |
| By: | /s/ Reid Waldman |
|  | Reid Waldman, M.D. |
|  | *Chief Executive Officer* |

---

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **SIGNATURE** | **TITLE** | **DATE** |
| /s/ Reid Waldman, M.D. | Chief Executive Officer and Director<br>*(Principal Executive Officer)* | April 29, 2026 |
| Reid Waldman, M.D. | Chief Executive Officer and Director<br>*(Principal Executive Officer)* | April 29, 2026 |
| /s/ Dominic Carrano, CPA | Chief Financial Officer and Treasurer<br>*(Principal Financial and Accounting Officer)* | April 29, 2026 |
| Dominic Carrano, CPA | Chief Financial Officer and Treasurer<br>*(Principal Financial and Accounting Officer)* | April 29, 2026 |
| \* | Director | April 29, 2026 |
| David Friedman, M.D. | Director | April 29, 2026 |
| \* | Director | April 29, 2026 |
| John W. Childs | Director | April 29, 2026 |
| \* | Director | April 29, 2026 |
| Vlad Coric, M.D. | Director | April 29, 2026 |
| \* | Director | April 29, 2026 |
| Katarina Pance, Ph.D. | Director | April 29, 2026 |
| \* | Director | April 29, 2026 |
| Patrick Enright | Director | April 29, 2026 |
| \* | Director | April 29, 2026 |
| Jane Grant-Kels, M.D. | Director | April 29, 2026 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Reid Waldman, M.D. |
|  | Reid Waldman, M.D. |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-1**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Veradermics, Inc**  |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation or Carry Forward Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.00001 per share | 457(a) | 567858 | $100.00 | $56785800.00 | 0.0001381 | $7842.12 |
| Fees to be Paid | 2 | Equity | Pre-Funded Warrants | Other |  |  |  | 0.0001381 | $0.00 |
| Fees to be Paid | 3 | Equity | Common Stock Underlying Pre-Funded Warrants | 457(a) | 0 | $0.00 | $0.00 | 0.0001381 | $0.00 |
| Fees Previously Paid |  |  |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $56785800.00  |  | $7842.12  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $7842.12  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (a) Represents only the additional number of securities being registered and includes 74,068 shares of common stock that may be sold if the underwriters exercise their option to purchase additional shares of common stock. Does not include the securities that the registrant previously registered on the Registration Statement on Form S-1, as amended (File No. 333-295356). (b) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price. The registrant previously registered shares of common stock, or Pre-Funded Warrants, having a proposed maximum aggregate offering price of $283,929,250.00 on a Registration Statement on Form S-1 (File No. 333-295356), which was declared effective by the Securities and Exchange Commission on April 29, 2026. In accordance with Rule 462(b) under the Securities Act, an additional amount of shares of common stock, or Pre-Funded Warrants, having a proposed maximum aggregate offering price of $56,785,800 is hereby registered, which includes shares of common stock that may be sold if the underwriters exercise their option to purchase additional shares of common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> (a) For each Pre-Funded Warrant sold, the number of shares of Common Stock to be offered will be reduced on a one-for-one basis. Accordingly, the proposed aggregate number of shares of Common Stock and Pre-Funded Warrants to be sold in the offering is 4,420,358, and the proposed maximum aggregate offering price of the Common Stock and the Pre-Funded Warrants (including the Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $442,035,800. In accordance with Rule 457(g), because the shares of Common Stock underlying the Pre-Funded Warrants are registered hereby, no separate registration fee is payable with respect to the Pre-Funded Warrants or the Common Stock issuable upon exercise thereof. Pursuant to Rule 457(g) under the Securities Act, no separate registration fee is required for these Pre-Funded Warrants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>3</sup> (a) In accordance with Rule 457(g), because the shares of Common Stock underlying the Pre-Funded Warrants are registered hereby, no separate registration fee is payable with respect to the Pre-Funded Warrants or the Common Stock issuable upon exercise thereof. Pursuant to Rule 457(g) under the Securities Act, no separate registration fee is required for these Pre-Funded Warrants. (b) Pursuant to Rule 416 under the Securities Act, the shares of Common Stock being registered hereby include an indeterminate number of shares of Common Stock that may be issuable as a result of stock splits, stock dividends or similar transactions.

---

| |
|:---|
| |
| **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims |
| Fee Offset Sources |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![ropesgraylogoa.jpg](ropesgraylogoa.jpg) | ROPES & GRAY LLP<br>PRUDENTIAL TOWER<br>800 BOYLSTON STREET<br>BOSTON, MA 02199-3600<br>WWW.ROPESGRAY.COM |

---

April 29, 2026

Veradermics, Incorporated

470 James St.

New Haven, CT 06513

Ladies and Gentlemen:

We have acted as counsel to Veradermics, Incorporated, a Delaware corporation (the "<u>Company</u>"), in connection with (i) the Registration Statement on Form S-1 (File No. 333-295356) (the "<u>Initial Registration Statement</u>") filed by the Company with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), and (ii) the second Registration Statement on Form S-1 filed by the Company pursuant to Rule 462(b) under the Securities Act (the "<u>462(b) Registration Statement</u>," and together with the Initial Registration Statement, the "<u>Registration Statement</u>"). This opinion letter is furnished to you in connection with the filing of the 462(b) Registration Statement, relating to the registration of up to (i) 567,858 shares of the common stock, $0.00001 par value per share, of the Company (the "<u>Shares</u>") or (ii) pre-funded warrants (the "<u>Pre-Funded Warrants</u>") to purchase 567,858 shares of common stock (the "<u>Warrant Shares</u>"), which includes Shares and Pre-Funded Warrants issuable upon the exercise of the underwriters' option to purchase additional Shares and Pre-Funded Warrants, if any. The Shares and Pre-Funded Warrants are proposed to be sold pursuant to an underwriting agreement (the "<u>Underwriting Agreement</u>") by and among the Company and Jefferies LLC, Leerink Partners LLC, Citigroup Global Markets Inc. and Cantor Fitzgerald & Co., as representatives of the underwriters named therein.

In connection with this opinion letter, we have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.

The opinions expressed below are limited to the Delaware General Corporation Law.

Based upon and subject to the foregoing, we are of the opinion that (i) the Shares have been duly authorized and, when issued and delivered pursuant to the Underwriting Agreement and against payment of the consideration set forth therein, will be, validly issued, fully paid and non-assessable, (ii) provided that the Pre-Funded Warrants have been duly executed and delivered by the Company and duly delivered to the purchaser thereof against payment therefor, then the Pre-Funded Warrants, when issued and sold as described in the prospectus included in the Registration Statement, assuming a sufficient number of Warrant Shares are at the time available for issuance, will be a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting creditors' rights generally and by general equitable principles (regardless of whether such enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith and fair dealing, and (iii) the Warrant Shares, when issued upon exercise of the Pre-Funded Warrants in accordance with its terms, will have been duly authorized and validly issued and will be fully paid and non-assessable.

We hereby consent to your filing this opinion as an exhibit to the 462(b) Registration Statement and to the use of our name therein and in the related prospectus under the caption "Legal Matters." In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/Ropes & Gray LLP

Ropes & Gray LLP

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-1 of our report dated March 30, 2026, relating to the financial statements of Veradermics, Incorporated appearing in the Annual Report on Form 10-K of Veradermics, Incorporated for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Hartford, Connecticut

April 29, 2026

<br>